Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial | MicrobiomeTrials← Back to trialsNCT07650240
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07-01Est. Completion: 2030-12-30
Enrollment target: 202 participants Locations- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Other microbiome trials you might be interested in
Biochemically Recurrent Prostate CarcinomaMetastatic Prostate CarcinomaProstate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhance…
Anchorage, United StatesEst. completion Dec 31, 2032
Clear Cell Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v7
This randomized phase III trial studies how well pazopanib hydrochloride works compared to placebo in treating patients …
Fairbanks, United StatesEst. completion Jul 17, 2018
Endometrial AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaEndometrioid AdenocarcinomaStage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olapari…
Birmingham, United StatesEst. completion Dec 6, 2024